Skip to main
PHVS

Pharvaris B.V. (PHVS) Stock Forecast & Price Target

Pharvaris B.V. (PHVS) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 20%
Buy 70%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Pharvaris is a compelling investment opportunity with a differentiated profile in the competitive HAE market, strong clinical data supporting their bradykinin B2 receptor antagonists, and significant market potential of ~€1B in peak sales. Their lead candidate, deucrictibant, has shown superiority in efficacy and tolerability in both on-demand and prophylactic settings compared to injectable options, with potential for even greater market share through physician willingness to switch patients from existing treatments. Recent financial updates also show strong cash position, providing runway into 2028.

Bears say

Pharvaris is a late-stage biopharmaceutical company with a negative outlook due to potential risks such as an increasingly crowded market for HAE treatments, experimental XR formulation being different from initial studies, and potential safety concerns. However, the company currently has a strong financial standing with €318 million on its balance sheet and a $40/share valuation based on a 10-year discounted cash flow analysis, assuming successful approval and launch of deucrictibant IR. The lack of diversity or social initiatives among senior management may also be a concern for some investors.

Pharvaris B.V. (PHVS) has been analyzed by 10 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 70% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pharvaris B.V. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pharvaris B.V. (PHVS) Forecast

Analysts have given Pharvaris B.V. (PHVS) a Buy based on their latest research and market trends.

According to 10 analysts, Pharvaris B.V. (PHVS) has a Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pharvaris B.V. (PHVS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.